Pfizer Inc., of New York, and Bristol-Myers Squibb Co., also of New York, said results of a pre-specified subanalysis of the phase III ARISTOTLE trial assessing the effect of blood pressure control on outcomes as well as the treatment effect of Eliquis (apixaban) compared to warfarin according to blood pressure control.